No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
zanubrutinib
BeiGene Press Release - 1 week
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
Truxima (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
CD20 expression
CD20 expression
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Truxima (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Rixathon (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
PCR
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ofatumumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
FCR
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
zanubrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
zanubrutinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
Chr del(11q)
Chr del(11q)
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib
Sensitive: A2 - Guideline
|
Chr del(11q)
Chr del(11q)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Resistant: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
ofatumumab
Resistant: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
idelalisib
Sensitive: A2 - Guideline
|
IGH mutation
IGH mutation
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib
Sensitive: A2 - Guideline
|
IGH mutation
IGH mutation
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab
Sensitive: A2 - Guideline
|
IGH mutation
IGH mutation
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
chlorambucil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
CD20 inhibitor + bendamustine
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
lenalidomide
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
lenalidomide
Sensitive: A2 - Guideline
|
TP53 deletion
TP53 deletion
|
Chronic Lymphocytic Leukemia
CLL
|
idelalisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
idelalisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
TP53 deletion
TP53 deletion
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib
Sensitive: A2 - Guideline
|
TP53 deletion
TP53 deletion
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
alemtuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
alemtuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
pembrolizumab + nivolumab + ibrutinib
Sensitive: A2 - Guideline
|
|
Chronic Lymphocytic Leukemia
CLL
|
acalabrutinib
Resistant: A2 - Guideline
|
IGH mutation
IGH mutation
|
Chronic Lymphocytic Leukemia
CLL
|
FCR
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
pembrolizumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
nivolumab
Sensitive: A2 - Guideline
|
Chr del(11q)
Chr del(11q)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
duvelisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
pembrolizumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
nivolumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
duvelisib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
OFAR
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
R-CVAD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
EPOCH-R
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
R-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
BR
Sensitive: A2 - Guideline
|
